Efficacy and safety of rituximab as second-line therapy in immune thrombocytopenic purpura based on ethnicity: A descriptive study among the Arabic population

Background: Rituximab is used as second-line therapy in patients with immune thrombocytopenic purpura (ITP) who do not respond to first-line management. The response rate for Rituximab is variable in different populations ranging from 30% to 90%. The adverse effects of rituximab in patients with ITP...

Descripción completa

Detalles Bibliográficos
Autores principales: Ata, Fateen, Yousaf, Zohaib, Zahir, Fathima Z., Mohamed Babiker, Anas, Ali Farooqi, Amer, Ahmad Al Hiyari, Mousa, Al Bozom, Adel Issam, Mohamed, Ahmed Hatim., Nashwan, Abdulqadir J., Yassin, Mohamed A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: HBKU Press 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9272691/
https://www.ncbi.nlm.nih.gov/pubmed/35864918
http://dx.doi.org/10.5339/qmj.2022.22

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9272691/
https://www.ncbi.nlm.nih.gov/pubmed/35864918
http://dx.doi.org/10.5339/qmj.2022.22

Ejemplares similares